Advertisement

The therapeutic effects of ginkgolides in Guillain-Barré syndrome and experimental autoimmune neuritis

      Highlights

      • Th17 cells and IFN-γ and IL-12p70 are involved in the pathogenesis and progression of GBS/EAN.
      • Administration of ginkgolides delayed the peak of disease and ameliorated the maximal scores of EAN in C57BL/6 mice might via down-regulating the proportions of Th17 cells in EAN spleens.
      • Ginkgolides suppressed inflammation response by decreasing pro-inflammatory cytokines IFN-γ and IL-12 in GBS patients.

      Abstract

      Background

      Guillain-Barré syndrome (GBS) is an acquired immune-mediated inflammatory peripheral neuropathy. The immune regulation of ginkgolides have been revealed in recent years. We herein investigate the potential therapeutic effects of ginkgolides both on GBS and its animal model, experimental autoimmune neuritis (EAN).

      Methods

      EAN in C57BL/6 mice induced by subcutaneous injection with peripheral nerve myelin P0 protein peptide 180–199 (P0 peptide) were treated with ginkgolides at three different doses. GBS patients were randomly divided into two groups, the experimental group and the control group. The experimental group were treated with ginkgolides as soon as diagnosed.

      Results

      Our data indicated that ginkgolides administration daily ameliorated the score of EAN and delayed the peak of disease in EAN mice. Ginkgolides also down-regulated the proportions of T helper (Th) 17 cells in EAN spleens. Furthermore, we also found that administration of ginkgolides significantly decreased the levels of interferon (IFN)-γ and interleukin-12 (IL)-12 in GBS patients.

      Conclusions

      Our results suggested that ginkgolides ameliorated the clinical score of EAN through down-regulating the proportions of Th 17 cells. Ginkgolides also suppressed inflammation response by decreasing pro-inflammatory cytokines IFN-γ and IL-12, suggesting ginkgolides had potential therapeutic effects on GBS patients and EAN in the future.

      Keywords

      Abbreviations:

      GBS (Guillain-Barré syndrome), EAN (experimental autoimmune neuritis), GB (ginkgolide B), PAF (platelet-activating factor), MNCs (mononuclear cells), IFN (interferon), IL (interleukin), p.i (post-immunization), Th (T helper), Treg (regulatory T), IVIg (immunoglobulin), HFGS (functional grading scale), MRC (Medical Research Council), CBA (cytometric beads array), (macrophages), NF-κB (nuclear factor-κB), TLR (toll-like receptors), MyD88 (myeloid differentiation factor 88)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Clinical Neuroscience
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Wakerley B.R.
        • Yuki N.
        Infectious and noninfectious triggers in Guillain-Barré syndrome.
        Expert Rev Clin Immunol. 2013; 9: 627-639
        • Zhu J.
        • Mix E.
        • Link H.
        Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barré syndrome.
        J Neuroimmunol. 1998; 84: 40-52
        • Strømgaard K.
        • Nakanishi K.
        Chemistry and biology of terpene trilactones from Ginkgo biloba.
        Angew Chem Int Ed Engl. 2004; 43: 1640-1658
        • Touvay C.
        • Vilain B.
        • Lejeune V.
        • Mencia-Huerta J.M.
        • Braquet P.
        Effect of cyclosporin A and the platelet-activating factor (PAF) antagonist, BN 52021, on PAF- and antigen-induced bronchoconstriction in the guinea-pig.
        Biochem Biophys Res Commun. 1989; 163: 118-123
        • Bellizzi M.J.
        • Geathers J.S.
        • Allan K.C.
        • Gelbard H.A.
        Platelet-activating factor receptors mediate excitatory postsynaptic hippocampal injury in experimental autoimmune encephalomyelitis.
        J Neurosci. 2016; 36: 1336-1346
        • Hughes R.A.
        • Newsom-Davis J.M.
        • Perkin G.D.
        • Pierce J.M.
        Controlled trial prednisolone in acute polyneuropathy.
        Lancet. 1978; 2: 750-753
        • Kleyweg R.P.
        • van der Meché F.G.
        • Schmitz P.I.
        Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome.
        Muscle Nerve. 1991; 14: 1103-1109
        • Reisin R.C.
        • Pociecha J.
        • Rodriguez E.
        • Massaro M.E.
        • Arroyo H.A.
        • Fejerman N.
        Severe Guillain-Barré syndrome in childhood treated with human immune globulin.
        Pediatr Neurol. 1996; 14: 308-312
        • Zhang H.-L.
        • Zheng X.-Y.
        • Zhu J.
        Th1/Th2/Th17/Treg cytokines in Guillain-Barré syndrome and experimental autoimmune neuritis.
        Cytokine Growth Factor Rev. 2013; 24: 443-453
        • Li S.
        • Yu M.
        • Li H.
        • Zhang H.
        • Jiang Y.
        IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barré syndrome.
        Mediators Inflamm. 2012; 2012260473
        • Harness J.
        • McCombe P.A.
        Increased levels of activated T-cells and reduced levels of CD4/CD25+ cells in peripheral blood of Guillain-Barré syndrome patients compared to controls.
        J Clin Neurosci. 2008; 15: 1031-1035
        • Gu J.-H.
        • Ge J.-B.
        • Li M.
        • Wu F.
        • Zhang W.
        • Qin Z.-H.
        Inhibition of NF-κB activation is associated with anti-inflammatory and anti-apoptotic effects of Ginkgolide B in a mouse model of cerebral ischemia/reperfusion injury.
        Eur J Pharm Sci. 2012; 47: 652-660
        • Jiang M.
        • Li J.
        • Peng Q.
        • Liu Y.
        • Liu W.
        • Luo C.
        • et al.
        Neuroprotective effects of bilobalide on cerebral ischemia and reperfusion injury are associated with inhibition of pro-inflammatory mediator production and down-regulation of JNK1/2 and p38 MAPK activation.
        J Neuroinflammation. 2014; 11: 167
        • Zhou J.-M.
        • Gu S.-S.
        • Mei W.H.
        • Zhou J.
        • Wang Z.Z.
        • Xiao W.
        Ginkgolides and bilobalide protect BV2 microglia cells against OGD/reoxygenation injury by inhibiting TLR2/4 signaling pathways.
        Cell Stress Chaperones. 2016; 21: 1037-1053
        • Mahmoud F.F.
        • Haines D.D.
        • Abul H.T.
        • Abal A.T.
        • Onadeko B.O.
        • Wise J.A.
        In vitro effects of astaxanthin combined with ginkgolide B on T lymphocyte activation in peripheral blood mononuclear cells from asthmatic subjects.
        J Pharmacol Sci. 2004; 94: 129-136
        • Wei H.
        • Sun T.
        • Tian Y.
        • Wang K.
        Ginkgolide B modulates BDNF expression in acute ischemic stroke.
        J Korean Neurosurg Soc. 2017; 60: 391-396
        • Zheng S.X.
        • Zhou L.J.
        • Chen Z.L.
        • Yin M.L.
        • Zhu X.Z.
        Bilobalide promotes expression of glial cell line-derived neurotrophic factor and vascular endothelial growth factor in rat astrocytes.
        Acta Pharmacol Sin. 2000; 21: 151-155
        • Zhang H.-L.
        • Azimullah S.
        • Zheng X.-Y.
        • Wang X.-K.
        • Amir N.
        • Mensah-Brown E.P.
        • et al.
        IFN-γ deficiency exacerbates experimental autoimmune neuritis in mice despite a mitigated systemic Th1 immune response.
        J Neuroimmunol. 2012; 246: 18-26
        • Nyati K.K.
        • Prasad K.N.
        Role of cytokines and Toll-like receptors in the immunopathogenesis of Guillain-Barré syndrome.
        Mediators Inflamm. 2014; 2014758639
        • Du Y.
        • Zhang G.
        • Zhang Z.
        • Wang Q.
        • Ma R.
        • Zhang L.
        • et al.
        Toll-like receptor 2 and -4 are involved in the pathogenesis of the Guillain-Barré syndrome.
        Mol Med Rep. 2015; 12: 3207-3213
        • Zhang Z.Y.
        • Zhang Z.
        • Schluesener H.J.
        Toll-like receptor-2, CD14 and heat-shock protein 70 in inflammatory lesions of rat experimental autoimmune neuritis.
        Neuroscience. 2009; 159: 136-142